871507-11-8 Usage
Quinoline core structure
The central framework of the compound is based on a quinoline ring, which is a tricyclic aromatic compound consisting of a benzene ring fused to a pyridine ring.
Pyridine ring
One of the side rings in the compound, which is a six-membered heterocyclic aromatic ring with one nitrogen atom.
Pyrazole ring
Another side ring in the compound, which is a five-membered heterocyclic aromatic ring with two nitrogen atoms.
Phenyl ring
A third side ring in the compound, which is a six-membered aromatic ring consisting of carbon atoms only.
Fused rings
The pyridine, pyrazole, and phenyl rings are all fused to the quinoline core, creating a complex three-dimensional structure.
Phenoxy group
A functional group consisting of a phenyl ring attached to an oxygen atom, which is attached to the 4-position of the phenyl ring in the compound.
Methyl group
A small alkyl group consisting of a single carbon atom bonded to three hydrogen atoms, which is attached to the nitrogen atom of the quinoline core.
Diverse chemical and biological properties
Due to the complex structure and presence of multiple functional groups, the compound is likely to exhibit a range of chemical and biological activities.
Potential applications in medicinal chemistry
The compound's diverse properties may make it useful for the development of new drugs and therapies.
Potential applications in material science
The unique structure and properties of the compound could be harnessed for the development of new materials with specific characteristics for various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 871507-11-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,1,5,0 and 7 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 871507-11:
(8*8)+(7*7)+(6*1)+(5*5)+(4*0)+(3*7)+(2*1)+(1*1)=168
168 % 10 = 8
So 871507-11-8 is a valid CAS Registry Number.
871507-11-8Relevant articles and documents
Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain
Tu, Zhude,Fan, Jinda,Li, Shihong,Jones, Lynne A.,Cui, Jinquan,Padakanti, Prashanth K.,Xu, Jinbin,Zeng, Dexing,Shoghi, Kooresh I.,Perlmutter, Joel S.,MacH, Robert H.
, p. 1666 - 1673 (2011/04/16)
2-((4-(1-[11C]Methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy) methyl)-quinoline (MP-10), a specific PDE10A inhibitor (IC50 = 0.18 nM with 100-fold selectivity over other PDEs), was radiosynthesized by alkylation of the desmethyl precursor with [11C]CH3I, ～45% yield, >92% radiochemical purity, >370 GBq/μmol specific activity at end of bombardment (EOB). Evaluation in Sprague-Dawley rats revealed that [11C]MP-10 had highest brain accumulation in the PDE10A enriched-striatum, the 30 min striatum: cerebellum ratio reached 6.55. MicroPET studies of [11C]MP-10 in monkeys displayed selective uptake in striatum. However, a radiolabeled metabolite capable of penetrating the blood-brain-barrier may limit the clinical utility of [11C]MP-10 as a PDE10A PET tracer.
Heteroaromatic quinoline compounds
-
Page/Page column 24, (2008/06/13)
The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.
